Each section of an amendment document (e.g., amendment to the claims, amendment to the specification, replacement drawings, and remarks) must begin on a separate sheet. (i) Amendments in reissue applications. Any amendment to the description and claims in reissue applications must be made in accordance with Â§ 1.173.
Prostatic calculi are common and are associated with inflammation of the prostate. Recently, it has been suggested that this inflammation may be associated with prostate carcinogenesis.
The Prostatic UroLift (PUL) Procedure (52441, 52442, C9739, C9740) The Prostatic UroLift (PUL), also known as the UroLift system or the transprostatic implant system has been researched for a less invasive procedure to manage BPH. The UroLift System received FDA authorization for marketing through a de novo classification approval on September 13, 2013 (K130651), as a Class II device.